Intestinal intraepithelial lymphocytes (IEL) reside within the single cell epithelial layer of the intestine[@R1], and are instrumental in safeguarding the integrity of mucosal immune responses. IEL contain two phenotypically distinct populations: conventional IEL, expressing the T cell receptor (TCR)αβ and either the co-receptor CD4 or heterodimers of CD8αβ, and unconventional IEL, which are either TCRαβ^+^ or TCRγδ^+^ and bear unique CD8αα homodimers.

TCRαβ^+^CD8αα^+^ IEL remain a somewhat elusive cell type, with their function and development still poorly understood. TCRαβ^+^CD8αα^+^ IEL exhibit an "activated but resting" phenotype and have been suggested to have a regulatory role within the gut[@R1]. They express high levels of CTLA-4, PD-1, Lag3 and transforming growth factor-β (TGF-β) and inhibitory NK receptors[@R2]-[@R4], molecules associated with immunoregulation. TCRαβ^+^CD8αα^+^ IEL prevent colitis when co-transferred with CD4^+^CD45RB^high^ T cells into immuno-compromised mice[@R5]. Lymphocytic choriomeningitis virus (LCMV) infection of transgenic mice which express an LCMV-reactive TCR plus a cognate antigen trans-gene reinforced the regulatory potential of TCRαβ^+^CD8αα^+^ IEL; upon infection, TCRαβ^+^CD8αα^+^ IEL showed signs of activation, however, unlike conventional IEL they did not become cytotoxic nor secrete pro-inflammatory cytokines[@R3]. The developmental pathway followed by TCRαβ^+^CD8αα^+^ IEL has been debated[@R6]; once thought to be of extra-thymic origin, TCRαβ^+^CD8αα^+^ IEL are now generally considered to arise in the thymus[@R7], [@R8], where the TCRαβ^+^CD8αα^+^ IEL precursors develop under the condition of a high affinity self-antigen-agonist[@R4], [@R9]. "Forbidden" TCRs have been identified in the TCRαβ^+^CD8αα^+^ IEL population[@R10]. However, the molecular pathways and regulatory factors controlling the development of TCRαβ^+^CD8αα^+^ IEL remain largely undetermined. Interleukin 15 (IL-15) was suggested to be required for their development, but IL-15 is not needed in the thymus, instead it maintains TCRαβ^+^CD8αα^+^ IEL in the gut[@R11].

The thymic "agonist selection" process utilized for the differentiation of TCRαβ^+^CD8αα^+^ IEL is shared with Foxp3^+^ regulatory T cells (Tregs)[@R12] and CD1-d restricted NK T cells (iNKT)[@R13]. Since both Foxp3^+^ Tregs[@R14] and iNKT[@R15] require TGF-β and TCR ligation to develop and differentiate, we questioned whether TGF-β was also required for the development of TCRαβ^+^CD8αα^+^ IEL. We show here that TGF-β controls TCRαβ^+^CD8αα^+^ IEL development. Mice with either a null mutation in TGF-β1 (*Tgfb1*^-/-^) or a T cell-specific deletion of TGF-β receptor I (TβRI) lacked TCRαβ^+^CD8αα^+^ IEL. In contrast, transgenic mice that over-expressed TGF-β1 had an increased population of TCRαβ^+^CD8αα^+^ IEL. Mechanistically, we show that TGF-β prevents apoptosis by regulating the expression of Bcl-2 and Bim and induces CD8α expression in TCRαβ^+^CD8αα^+^ IEL thymic precursors. TGF-β regulation of CD8α expression was not limited to the IEL, but was rather a more general phenomenon, as TGF-β induced the re-expression of repressed CD8α in lineage committed peripheral CD4^+^ T cells. CD8α expression was associated with suppression of Th-POK up-regulation and prevention of Runx3 down-regulation in CD4^+^ T cells. Thus we demonstrate a previously unrecognized role for TGF-β-signaling in the development of TCRαβ^+^CD8αα^+^ IEL and in the expression of CD8α in TCRαβ^+^ cells.

Results {#S1}
=======

TGF-β deficiency reduces TCRαβ^+^CD8αα^+^ IEL {#S2}
---------------------------------------------

During the perinatal period lymphocytes accumulate in the gut, with a fully mature complement of IEL being present by three weeks of age[@R16], [@R17]. We examined the IEL populations in *Tgfb1*^-/-^ mice during this period of epithelial colonization by lymphocytes. TCRαβ^+^CD8αα^+^ IEL were significantly reduced in *Tgfb1*^-/-^ mice, most notably after two to three weeks of age ([Fig.1a-c](#F1){ref-type="fig"}). The decrease in TCRαβ^+^CD8αα^+^ IEL was accompanied by an increase in TCRαβ^+^CD8αβ^+^ IEL. The decrease in TCRαβ^+^CD8αα^+^ IEL was significant both in terms of frequency within TCRαβ^+^ lymphocytes of the gut ([Fig.1b](#F1){ref-type="fig"}), or total cell numbers ([Fig.1c](#F1){ref-type="fig"}) despite the overall increase in TCRαβ^+^ T cells that accompanies the systemic inflammation seen in *Tgfb1*^-/-^ mice[@R18]. In contrast, there was no reduction in the frequency or total numbers of TCRγδ^+^CD8αα^+^ IEL in *Tgfb1*^-/-^ mice ([Fig.1d-f](#F1){ref-type="fig"}). These data suggest TGF-β plays a role in the development of TCRαβ^+^CD8αα^+^ IEL.

We next determined whether the requirement for TGF-β in the generation of TCRαβ^+^CD8αα^+^ IEL was T cell autonomous by using mice in which TβRI was specifically deleted in T cells (*Tgfbr1*^f/f^CD4-cre^+^)[@R14]. Examination of IEL in these mice revealed that they also lacked TCRαβ^+^CD8αα^+^ IELs ([Fig.1g](#F1){ref-type="fig"}). *Tgfbr1*^f/f^CD4-cre^+^ mice had a reduction in the frequency and total number of TCRαβ^+^CD8αα^+^ IEL ([Fig.1h, i](#F1){ref-type="fig"}), but not in TCRγδ^+^CD8αα^+^ IEL ([Fig.1j-l](#F1){ref-type="fig"}). We also examined the IEL compartment in mixed bone marrow chimeras generated using CD45.1^+^ wild-type mixed with CD45.2^+^*Tgfbr1*^f/f^CD4-cre^+^ or CD45.2^+^ *Tgfbr1*^f/+^CD4-cre^+^ donor cells injected into recombination-activating gene-1-deficient (*Rag1*^-/-^) hosts. IEL populations derived from *Tgfbr1*^f/f^CD4-cre^+^ bone marrow had a significantly lower proportion of TCRαβ^+^CD8αα^+^ IEL compared to both CD45.1^+^ and *Tgfbr1*^f/+^CD4-cre^+^ controls ([Supplementary Fig.1](#SD1){ref-type="supplementary-material"}). Thus, deletion of TGF-β signaling resulted in defective development of TCRαβ^+^CD8αα^+^ IEL.

Canonical TGF-β signaling requires members of the Smad protein family[@R19]. *Smad3*^-/-^ mice showed a significant reduction in the frequency of TCRαβ^+^CD8αα^+^ IEL compared to littermate controls ([Fig.2](#F2){ref-type="fig"}), suggesting Smad3 plays a role downstream of TGF-β in TCRαβ^+^CD8αα^+^ IEL generation.

Over-expression of TGF-β1 increases TCRαβ^+^CD8αα^+^ IEL {#S3}
--------------------------------------------------------

We next examined the IEL populations in mice that over-expressed active TGF-β1 specifically in T cells ([Supplementary Fig. 2](#SD1){ref-type="supplementary-material"}). In β1^glo+^CD4-cre^+^ mice expression of an active TGF-β1, which is unable to associate with the latency associated protein (LAP), is driven by an ubiquitous promoter and marked by loss of eGFP expression[@R20]. These mice showed no signs of overt immune dysregulation (data not shown). However, TCRαβ^+^CD8αα^+^ IELs were significantly enhanced in β1^glo+^CD4-cre^+^ mice compared to non-transgenic littermate controls ([Fig.3](#F3){ref-type="fig"}), further suggesting that TGF-β is required for the development of this population.

TGF-β deficiency reduces TCRαβ^+^CD8αα^+^ IEL precursors {#S4}
--------------------------------------------------------

TCRαβ^+^CD8αα^+^ IEL precursors are found within a population of CD4^−^CD8^−^ double negative (DN) thymocytes which have a functionally rearranged TCR, thus have undergone positive selection, and are positive for CD5[@R7] ([Fig. 4a](#F4){ref-type="fig"}). We investigated whether lack of TGF-β signaling affected their generation and/or phenotype. *Tgfb1*^-/-^ mice ([Fig.4b](#F4){ref-type="fig"}) and *Tgfbr1*^f/f^CD4-cre^+^ mice ([Supplementary Fig.3](#SD1){ref-type="supplementary-material"}) had a significant reduction in the frequency of DN TCRαβ^+^CD5^+^ thymocytes, but not in the frequency of total DN thymocytes ([Fig.4b](#F4){ref-type="fig"} and [Supplementary Fig. 3](#SD1){ref-type="supplementary-material"}). Increased cell death was observed in the DN TCRαβ^+^CD5^+^ thymocyte compartment in *Tgfb1*^-/-^ mice compared to wild-type controls ([Fig.4c](#F4){ref-type="fig"}). TGF-β-signaling is known to inhibit T cell apoptosis associated with increased mitochondria permeability[@R21] and with imbalances in the expression of pro- and anti-apoptotic Bcl-2 family members[@R22]. DN TCRαβ^+^CD5^+^ thymocytes from *Tgfb1*^-/-^ mice had reduced expression of the pro-survival protein Bcl-2 ([Fig.4d](#F4){ref-type="fig"}) and increased expression of the pro-apoptotic protein Bim ([Fig.4e](#F4){ref-type="fig"}). This was not the case for the total DN population, which, in *Tgfb1*^-/-^ mice, exhibited enhanced expression of both Bim and Bcl-2 compared to wild-type controls, and, as previously described[@R21], showed no increase in apoptosis ([Supplementary Fig.4](#SD1){ref-type="supplementary-material"}). Thus, TGF-β1 is required for the protection of DN TCRαβ^+^CD5^+^ thymocytes from cell death by safeguarding the balanced expression of Bcl-2 family members.

We used Ki-67 staining to look for a proliferation defect in TGF-β1-deficient DN TCRαβ^+^CD5^+^ thymocytes. *Tgfb1*^-/-^ DN TCRαβ^+^CD5^+^ thymocytes exhibited no proliferative defect, rather there were more dividing (Ki-67^+^) cells ([Fig.4f](#F4){ref-type="fig"}). This was in contrast to the total DN thymocyte population, which had similar frequencies of Ki-67^+^ cells in *Tgfb1*^-/-^ and wild-type thymi ([Supplementary Fig.4](#SD1){ref-type="supplementary-material"}). These data suggest that TGF-β protects DN TCRαβ^+^CD5^+^ from death and exclude decreased precursor expansion as the primary cause for the lack of TCRαβ^+^CD8αα^+^ IEL in TGF-β-deficient mice.

Phenotypic alterations of thymic precursors in TGF-β-deficient mice {#S5}
-------------------------------------------------------------------

We further examined if TGF-β1-deficient DN TCRαβ^+^CD5^+^ thymocytes exhibited an altered phenotype that could influence their function, survival and/or migration to the gut. The few remaining DN TCRαβ^+^CD5^+^ thymocytes in *Tgfb1*^-/-^ mice exhibited lower expression levels of IL-7 receptor α (CD127) ([Fig.4g](#F4){ref-type="fig"}). IL-7 has both pro-survival effects for thymocytes[@R23] and is implicated in CD8 lineage choice[@R24], however, it remains unclear whether CD127 down-regulation has a causative role or just accompanies the TGF-β-mediated decrease in DN TCRαβ^+^CD5^+^ thymocytes. IL-2 causes down-regulation of CD127 expression[@R25] and TGF-β-deficient mice have increased IL-2 levels[@R14]. However, heightened amounts of IL-2 cannot account for lack of TCRαβ^+^CD8αα^+^ IEL in TGF-β-deficient mice, as *IL-2^-/-^* × *Tgfbr1*^f/f^Lck-cre^+^ (IL-2 and TβRI double knockout) mice do not have TCRαβ^+^CD8αα^+^ IELs, and *IL-2^-/-^* mice do not have enhanced frequencies of these cells ([Supplementary Fig.5](#SD1){ref-type="supplementary-material"}). IL-15 is also involved in TCRαβ^+^CD8αα^+^ IEL generation[@R11], however we saw no alteration in IL-15R expression that could account for decreased TCRαβ^+^CD8αα^+^ IEL in TGF-β-deficient mice ([Supplementary Fig.5](#SD1){ref-type="supplementary-material"}).

We next examined expression of adhesion molecules important for gut homing. Integrin α4β7 is important for trafficking of recent thymic emigrants (RTE) to the gut epithelium[@R26] and is thought to direct homing of TCRαβ^+^CD8αα^+^ IEL precursors to the gut mucosa[@R6], [@R27]. Wild-type DN TCRαβ^+^CD5^+^ thymocytes expressed α4β7 ([Fig.4h](#F4){ref-type="fig"}). The frequency of α4β7^+^ cells was increased in *Tgfb1*^-/-^ mice ([Fig.4h](#F4){ref-type="fig"}), ruling out aberrant α4β7^+^-mediated gut homing of precursors. CD103 expression, which is dependent on TGF-β[@R28], was reduced on DN TCRαβ^+^CD5^+^ thymocytes from *Tgfb1*^\--/-^ mice ([Fig.4i](#F4){ref-type="fig"}). However, CD103 is not required for trafficking of RTEs to the gut[@R26]. These data suggest that defective generation of TCRαβ^+^CD8αα^+^ IEL in TGF-β-deficient mice could not be attributed to phenotypic changes affecting DN TCRαβ^+^CD5^+^ thymocyte gut homing and/or IL-7 responsiveness.

TGF-β induces CD8α expression in DN TCRαβ^+^CD5^+^ thymocytes {#S6}
-------------------------------------------------------------

Although total DN thymocytes in TGF-β-deficient mice displayed normal survival, other thymocyte populations, such as single positive CD4^+^ and CD8^+^ and double positive thymocytes showed enhanced cell death[@R21] and changes in the reciprocal expression of Bcl-2 and Bim similar to DN TCRαβ^+^CD5^+^ thymocytes ([Supplementary Fig.4](#SD1){ref-type="supplementary-material"} and data not shown). To further elucidate the mechanisms by which TGF-β controls TCRαβ^+^CD8αα^+^ IEL development, we determined whether TGF-β1 could induce CD8α expression in the DN TCRαβ^+^CD5^+^ thymocytes. DN TCRαβ^+^CD5^+^ thymocytes were sorted from wild-type mice and cultured with TCR-simulation and with or without TGF-β1. TGF-β1 induced CD8α mRNA in DN TCRαβ^+^CD5^+^ thymocytes ([Fig.5a](#F5){ref-type="fig"}) without affecting CD8β expression ([Fig.5b](#F5){ref-type="fig"}).

To determine what transcription factors were involved in the TGF-β mediated induction of CD8α expression in DN TCRαβ^+^CD5^+^ thymocytes, we examined the expression of Runx3 and Th-POK in DN TCRαβ^+^CD5^+^ thymocytes and TCRαβ^+^CD8αα^+^ IEL. Runx3 and Th-POK are transcription factors important in CD4 and CD8 lineage commitment; Runx3 inhibits CD4 and promotes CD8 T cell differentiation, and Th-POK inhibits CD8 and promotes CD4 T cell differentiation[@R29]. Using fluorescent-protein reporter mice[@R30], [@R31] to examine Runx3 and Th-POK expression, we saw that a similar proportion of DN TCRαβ^+^CD5^+^ thymocytes and TCRαβ^+^CD8αα^+^ IEL were Runx3 positive, but no TCRαβ^+^CD8αα^+^ IEL and few TCRαβ^+^CD5^+^ thymocytes were Th-POK positive ([Supplementary Fig.6](#SD1){ref-type="supplementary-material"}), suggesting that the TCRαβ^+^CD8αα^+^ IEL program is set in the thymus. In addition, in DN TCRαβ^+^CD5^+^ thymocytes cultured under TCR-stimulation conditions, TGF-β1 did not change the proportion of Runx3^+^ DN TCRαβ^+^CD5^+^ thymocytes (data not shown), nor the amount of Runx3 expressed per cell (MFI) ([Supplementary Fig.6](#SD1){ref-type="supplementary-material"}). However, TGF-β1 treatment resulted in a lower proportion of Th-POK-positive TCRαβ^+^CD5^+^ thymocytes compared to control cultures ([Supplementary Fig.6](#SD1){ref-type="supplementary-material"}). These data suggest that TGF-β alters the balance of these lineage commitment transcription factors in DN TCRαβ^+^CD5^+^ thymocytes to favor CD8α expression. Confirming a direct effect of TGF-β on Th-POK transcription, TGF-β1 reduced Th-POK mRNA amounts in sorted DN TCRαβ^+^CD5^+^ thymocytes cultured under TCR-stimulating conditions ([Fig.5c](#F5){ref-type="fig"}). In addition, DN TCRαβ^+^CD5^+^ thymocytes from *Tgfb1*^-/-^ mice had increased expression of Th-POK mRNA compared to littermate controls ([Supplementary Fig.6](#SD1){ref-type="supplementary-material"}). These data suggest that TGF-β favors CD8 expression by reducing Th-POK in the presence of maintained Runx3 expression.

TGF-β maintains CD8 expression on CD8^+^ T cells {#S7}
------------------------------------------------

The demonstration that TGF-β could induce CD8α mRNA in DN TCRαβ^+^CD5^+^ thymocytes prompted us to ask whether TGF-β could also affect the levels of CD8α expression in other TCRαβ^+^ T cell populations. In total TCRαβ^+^CD8^+^ (CD8αα^+^ and CD8αβ^+^) IELs and TCRαβ^+^CD8αβ^+^ IEL CD8α expression on a per cell basis was lower in TGF-β-deficient mice compared to controls ([Fig.1](#F1){ref-type="fig"}, [Supplementary Fig.7](#SD1){ref-type="supplementary-material"} and data not shown), despite the increased frequency of TCRαβ^+^CD8αβ^+^IEL in TGF-β-deficient mice ([Fig.1](#F1){ref-type="fig"}). In addition, peripheral CD8^+^ T cells in *Tgfb1*^-/-^ ([Fig.6a, b](#F6){ref-type="fig"}) and *Tgfbr1*^f/f^CD4-cre^+^ mice ([Fig.6c, d](#F6){ref-type="fig"}) exhibited a lower expression of CD8α per cell. CD8β expression was also reduced on TCRβ^+^CD8αβ^+^ and peripheral CD8^+^ T cells in TGF-β-deficient mice ([Fig.6](#F6){ref-type="fig"}). Reduced CD8 expression was accompanied by reduced frequencies of CD8^+^ T cells, as reported for TGF-β-deficient mice[@R32], and was detected on live and naïve TCRαβ^+^CD8^+^ gated cells ([Supplementary Fig.7](#SD1){ref-type="supplementary-material"}), suggesting decreased CD8 expression was unlikely due to cell death or activation. Expression of CD8 was also specifically reduced on *Tgfbr1*^f/f^CD4-cre^+^ cells in mixed bone-marrow chimeras ([Supplementary Fig.7](#SD1){ref-type="supplementary-material"}), suggesting a T cell intrinsic effect. Notably, decreased co-receptor expression was not seen in CD4^+^ T cells ([Fig.6](#F6){ref-type="fig"} and [Supplementary Fig.7](#SD1){ref-type="supplementary-material"}), indicating a specific role for TGF-β in maintaining CD8 expression. Consistent with these *in vivo* observations, addition of TGF-β to cultures of peripheral wild-type CD8^+^ T cells increased the expression of CD8α on a per cell basis (MFI) ([Supplementary Fig.8](#SD1){ref-type="supplementary-material"}). These data indicate that TGF-β maintains CD8α expression not only in TCRαβ^+^ IELs, but also in peripheral CD8^+^ T cells.

TGF-β induces expression of CD8α in CD4^+^ T cells {#S8}
--------------------------------------------------

T cells expressing both CD4 and CD8 exist *in vivo*[@R33], and adoptive transfer of CD4^+^ T cells into *Rag1^-/-^* mice leads to differentiation of a CD4^+^CD8αα ^+^ population specifically in the gut[@R34]. Thus, we examined whether TGF-β could induce CD8α expression on CD4^+^ T cells. A small fraction of peripheral CD4^+^ T cells, a population with no CD8α expression, became CD8α^+^ when cultured with TGF-β1 *in vitro* ([Fig.7a](#F7){ref-type="fig"}). The induction of CD8α on CD4^+^ T cells occurred whether the starting population was sorted naïve T cells, CD4^+^CD62L^hi^ cells ([Supplementary Fig.9](#SD1){ref-type="supplementary-material"}), or sorted CD4^+^CD25^-^ cells ([Fig.7](#F7){ref-type="fig"}). TGF-β-dependent induction of CD8α on CD4^+^ T was independent of CD28-costimulation, since CD8α was induced in the presence and absence of anti-CD28 (data not shown and [Supplementary Fig.9](#SD1){ref-type="supplementary-material"}). Of those cells that were induced to express CD8α, one-third were CD8β^-^ (CD4^+^CD8αα^+^), while the remaining cells co-expressed CD8β.

To confirm this was indeed *de novo* induction of CD8α expression, we examined CD8α mRNA expression in TGF-β1-treated CD4^+^ T cells before proliferation of the cultured cells. At 6 hours following TGF-β1-treatment, CD8α gene transcription had already significantly increased in CD4^+^ T cells ([Fig.7b](#F7){ref-type="fig"}), with an even greater enhancement of CD8α mRNA at 48 hours. CD8β mRNA expression was not increased at 6 hours and was decreased at later time points ([Fig.7b](#F7){ref-type="fig"}). Thus, similar to DN TCRαβ^+^CD5^+^ thymocytes, TGF-β1 induces CD8α expression in CD4^+^ T cells.

Mechanisms of CD8α expression by TGF-β {#S9}
--------------------------------------

We next determined the mechanism(s) of TGF-β-mediated induction of CD8α on CD4^+^ T cells. Induction of CD8α occurred in wild-type CD4^+^ T cells cultured with TGF-β1, but no CD4^+^CD8α^+^ T cells emerged in *Smad3*^-/-^ T cell cultures ([Fig.7c](#F7){ref-type="fig"}). In addition, *Smad3*^-/-^ CD4^+^ T cells failed to show up-regulation of CD8α mRNA following stimulation in the presence of TGF-β1 ([Fig.7b](#F7){ref-type="fig"}). Thus, Smad3 is required for TGF-β induction of CD8α in CD4^+^ cells.

We also examined if, similar to DN TCRαβ^+^CD5^+^ thymocytes, an alteration in the expression of the lineage commitment transcription factors Th-POK and/or Runx3 could also be found in peripheral CD4^+^ T cells during TGF-β-mediated CD8α induction. Using Runx3 reporter mice[@R30] we showed that TCR activation up-regulated Runx3 in CD4^+^ T cells ([Fig.8a](#F8){ref-type="fig"}). Addition of TGF-β1 to these cultures considerably reduced Runx3 expression in the emerging CD4^+^CD8^-^ subset, but had no such effect on the converted CD4^+^CD8α^+^ population ([Fig.8a](#F8){ref-type="fig"}). These data indicate that resistance to TGF-β-mediated Runx3 down-regulation was associated with CD8α induction in CD4^+^ T cells, although whether this maintenance of Runx3 has a causative effect on CD8α expression remains to be elucidated.

Lack of Th-POK in peripheral CD4^+^ T cells allows re-expression of CD8[@R35]. Using Th-POK reporter mice[@R31], we show that CD4^+^ T cell activation caused increased expression of Th-POK, consistent with previous studies[@R35]. However, addition of TGF-β1 to cultures abrogated the activation-induced increase in Th-POK expression ([Fig.8b](#F8){ref-type="fig"}), suggesting that TGF-β1 had an inhibitory effect on Th-POK expression. There was a slight, but reproducible, decrease in Th-POK levels in CD4^+^CD8α^+^ T cells compared to CD4^+^CD8α^-^ single positive cells in TGF-β1 treated cultures ([Fig.8c](#F8){ref-type="fig"}). In addition, TGF-β1 treatment of CD4^+^ T cells from *Zbtb7b*^+/-^ (Th-POK heterozygous) mice[@R31], which express half the amount of Th-POK, led to increased frequencies of CD4^+^CD8α^+^ cells compared to wild-type controls ([Fig.8d](#F8){ref-type="fig"}). In contrast, TGF-β1 treatment of CD4^+^ T cells from mice that constitutively express Th-POK in T cells[@R36], showed reduced frequencies of CD4^+^CD8α^+^ T cells ([Fig.8e](#F8){ref-type="fig"}). Collectively, our data indicate that even slight changes in the expression levels of the fate-determining factors Th-POK and Runx3 allow CD8α expression on CD4^+^ T cells. In particular, they suggest that a key step in inducing CD8α in CD4^+^ T cells by TGF-β, is the down-regulation of Th-POK.

Because transfer of activated CD4^+^ T cells into *Rag1^-/-^* mice leads to the generation/conversion of CD4^+^CD8αα^+^ T cells in the intraepithelial space of the gut[@R34], we determined whether this effect was TGF-β-dependent by injecting *in vitro* activated CD4^+^ T cells from *Tgfbr1*^f/+^CD4-cre^+^ or *Tgfbr1*^f/f^CD4-cre^+^ mice into *Rag1^-/-^* mice. As reported, after 4 weeks a proportion of control CD4^+^ T cells became CD4^+^CD8α^+^ in the intraepithelial space ([Supplementary Fig.10](#SD1){ref-type="supplementary-material"})[@R34]. However, this was not the case when TβRI-deficient CD4^+^ T cells were transferred. No CD4^+^CD8α^+^ T cells were found in the spleen in either group (data not shown). These data indicate that TGF-β can function *in vivo* to drive expression of CD8α on a CD4+ population.

Discussion {#S10}
==========

Here we demonstrate that TGF-β is an essential regulator in the control of TCRαβ^+^CD8αα^+^ IEL development. Deletion of TGF-β ligand or receptor abrogated TCRαβ^+^CD8αα^+^ IEL development. Deletion of the important TGF-β-signaling intermediate Smad3, also led to a decrease in TCRαβ^+^CD8αα^+^ IEL. Over-expression of TGF-β1 in T cells enhanced TCRαβ^+^CD8αα^+^ IEL development. The defective development of IELs in the absence of TGF-β-signaling was restricted to the TCRαβ^+^CD8αα^+^ subset, while neither TCRαβ^+^CD8αβ^+^ nor TCRγδ^+^CD8αα^+^ populations decreased. TGF-β was required for the generation of thymic precursors (DN TCRαβ^+^CD5^+^) of TCRαβ^+^CD8αα^+^ IELs and protected these cells from death.

Consistent with an anti-apoptotic role for TGF-β in T cells[@R21], TGF-β functions to enhance the levels of pro-survival Bcl-2 and reduce expression levels of pro-apoptotic Bim molecules in DN TCRαβ^+^CD5^+^ thymocytes. Although TGF-β protection from cell death seems important, it may not be the sole mechanism for lack of TCRαβ^+^CD8αα^+^ IEL in the absence of TGF-β, as other populations of thymocytes exhibited increased Bim and decreased Bcl-2 expression and enhanced cell death similar to DN TCRβ^+^CD5^+^ thymocytes (a definite causative effect of changes in Bcl-2 and Bim on cell death in most TGF-β-deficient thymocytes remains to be determined). Thus, protection from apoptosis may represent only part of the complex molecular events by which TGF-β controls TCRαβ^+^CD8αα^+^ IEL development. Indeed, TGF-β could induce CD8α in DN TCRαβ^+^CD5^+^ thymocytes. TGF-β also decreased the expression of Th-POK, which inhibits CD8 expression, in DN TCRαβ^+^CD5^+^ thymocytes, providing further mechanisms of TGF-β-mediated control of TCRαβ^+^CD8αα^+^ IEL development.

Our finding that TGF-β, in addition to inducing expression of CD8α in DN TCRβ^+^CD5^+^ thymocytes, maintains and/or increases CD8α expression on TCRαβ^+^ cells which already express CD8α, provides an additional mechanism for TGF-β regulation of TCRαβ^+^CD8αα^+^ IEL development. In a similar way, TGF-β induces the expression of Foxp3 in CD4^+^Foxp3^-^ cells[@R37], but also maintains its expression in Foxp3^+^Tregs[@R38]. Decreased CD8α expression in peripheral CD8^+^ T cells in TGF-β-deficient mice was not due to either cell death or activation, and was cell intrinsic, because peripheral CD8^+^ T cells lacking TβRI expression in bone marrow chimeras also had lower CD8 expression levels.

Induction of CD8α, as shown in DN TCRβ^+^CD5^+^ thymocytes, was also seen in peripheral CD4^+^ T cells, and therefore could be a general feature of TGF-β signaling. Reprogramming of peripheral CD4^+^ T cells by TGF-β was particularly unexpected, as peripheral CD4^+^ T cells have active mechanisms that repress CD8 expression. A previous study reported that CD4^+^ T cells isolated from the gut, but not the spleen, expressed CD8αα following transfer into *Rag1^-/-^* recipients[@R34]. The gut is a TGF-β rich environment. We confirmed these experiments and further showed that transferred CD4^+^ cells that cannot respond to TGF-β do not express CD8α in the gut. A small population of TCRαβ^+^CD4^+^CD8α^+^ is found in the epithelial cell layer of the gut in the steady-state[@R39], but the cellular origin and molecular regulation of their development remain unknown. Thus, our data raise the possibility that TCRαβ^+^CD8αα^+^ IEL consist of a subpopulation converted from mature CD4^+^ or CD8αβ^+^ T cells in the TGF-β-rich mucosal intra-epithelial space.

Further analysis of TGF-β-induced CD4^+^CD8α^+^ cells identified both CD4^+^CD8αα^+^ and CD4^+^CD8αβ^+^ populations. Although we see expression of both CD8α and CD8β on the surface of the CD4^+^ T cell cultured in the presence of TGF-β, only CD8α mRNA was induced by TGF-β. CD4^+^ T cells have been reported to constitutively express CD8β[@R40], but CD8β can only reach the cell surface in the presence of CD8α[@R41]. Hence induction of CD8α only, and not CD8β, might be sufficient to induce the expression of CD8αβ heterodimers at the cell surface.

If CD4^+^ T cells have transcriptional programs repressing CD8 expression, then induction of CD8α in CD4^+^ T cells indicates TGF-β actively reverses a "repressor" and/or promotes an "enhancer" of the CD8α gene transcription program. Our observations showed that TGF-β affected the expression of two transcription factors important in lineage commitment; Th-POK and Runx3. Compared with CD4^+^ cells cultured with TCR stimulation alone, TGF-β treatment caused a considerable decrease in Th-POK expression, which could explain CD8α expression in CD4^+^ T cells. Reduction in Th-POK expression in CD4^+^ T cells was shown to allow for the induction of CD8, and maintaining Th-POK at high levels is important in keeping the CD8 program repressed[@R35]. We confirmed this view by examining CD8α-induction in CD4^+^ T cells from mice that express different amounts of Th-POK protein. Thus, a decrease in Th-POK expression following TGF-β treatment could release CD8 repression, allowing CD8α expression on CD4^+^ T cells.

Alternatively, but nonexclusively, a complementary change of positive factors could collaboratively accomplish CD8α expression on CD4^+^ cells. Runx3 is mainly associated with the repression of CD4 and CD4-fate genes, but is known to bind to CD8 enhancers, predominately E8~I~[@R42]. We observed increased levels of Runx3 in CD4^+^CD8α^+^ compared to CD4^+^CD8α^-^ cells in TGF-β treated cultures. Thus, in contrast to Th-POK, the levels of Runx3 expression in the converted CD4^+^CD8α^+^ population were higher than that in CD4^+^CD8α^-^ cells. Therefore we suggest that TGF-β can alter the balance of these two transcription factors within the cell to create an environment favorable for the expression of CD8α in CD4^+^ T cells. In addition, induction of CD8α on CD4^+^ T cells was Smad3 dependent, and interestingly Runx proteins and the Smad proteins have been shown to interact to regulate the IgCα promoter[@R43]. Other members of the TGF-β-super-family, such as the BMP (bone morphogenic proteins), have long been known to activate Runx proteins[@R44]. Runx proteins have also been shown to be important downstream mediators in the TGF-β-induced expression of Foxp3 and CD103[@R45], [@R46]. Whether TGF-β-mediated down-regulation of Th-POK is downstream of Smad proteins remains to be elucidated, but our data clearly link TGF-β signaling to Th-POK down-regulation.

Further, we show that TGF-β-signaling affected the balance between Th-POK and Runx3 in DN TCRαβ^+^CD5^+^ thymocytes. Thus, despite the different transcription networks active in TCRαβ^+^CD8αα^+^ precursors and CD4^+^ T cells, TGF-β has the overall ability to alter Th-POK and Runx3 expression in a direction that favors CD8α expression.

If TGF-β can induce CD8α expression, it remains unclear why TGF-β deficient mice only lack the TCRαβ^+^CD8αα^+^ but not the TCRαβ^+^CD8αβ^+^ or TCRγδ^+^CD8αα^+^ IELs. TCRγδ^+^ and TCRαβ^+^ T cells undergo distinct developmental programs, and indeed TGF-β could represent a signal specific for the TCRαβ^+^CD8αα^+^ cell fate. The CD8 enhancer E8~I~ is required for CD8α gene expression in CD8αα^+^ IEL[@R47], so TGF-β signaling may affect E8~I~ regulation. Regarding the functional effect of CD8α expression in CD4^+^ T cells, phenotypic examination of cells from TGF-β treated cultures showed that CD4^+^CD8α^-^ and CD4^+^CD8α^+^ cells expressed similar levels of Foxp3, and no increased expression of proteins associated with CD8-fate were seen in CD4^+^CD8α^+^ cells (data not shown). The presence of CD4^+^CD8^+^ T cells has been described in a number of normal and pathological conditions[@R33], including autoimmune disorders and cancer. It will be interesting to examine the mechanisms by which these cells arise.

In conclusion, our findings highlight an intriguing common developmental pathway of "self-reactive" T cell populations such that Foxp3^+^ Treg cells, iNKT cells, and now TCRαβ^+^CD8αα^+^ IEL, all require TGF-β for their development.
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![Reduction of TCRαβ^+^CD8αα^+^ IEL in mice which lack TGF-β-signaling\
(**a, d**) Representative plots showing CD8α versus CD8β staining on TCRβ^+^ (**a**) and TCRγδ^+^ (**d**) cells in 2-3-week-old *Tgfb*1^-/-^and age-matched littermate control wild-type (WT) mice. (**b**) frequency and (**c**) total number of CD8αβ^+^ or CD8αα^+^ TCRαβ^+^ IEL in mice from **a** (mean ± SEM). (**e**) frequency and (**f**) total number of CD8αα^+^ TCRαβ^+^ IELs in mice from (**d**) (mean ± SEM). *n*=8 for *Tgfb1*^-/-^ (black bars) and *n*=8 for wild-type controls (white bars). (**g, j**) Representative plots showing CD8α versus CD8β staining on TCRβ^+^ (**g**) and TCRγδ^+^ (**j**) cells in 3-4 week old *Tgfbr1*^f/f^CD4-Cre^+^ and age-matched littermate control *Tgfbr1*^f/+^CD4-cre^+^ mice. (**h**) frequency and (**i**) total number of CD8αβ^+^ or CD8αα^+^ TCRαβ^+^ IEL in mice from (**g**) (mean ± SEM). (**k**) frequency and (**l**) total number of CD8αα^+^ TCRαβ^+^ IELs in mice from (**j**) (mean ± SEM). *n*=18 for *Tgfbr1*^f/f^CD4-cre^+^ (black bars) and *n*=19 for *Tgfbr1*^f/+^ CD4-cre^+^ mice (white bars). \*p\<0.05, \*\*p\<0.005, \*\*p\<0.0001 (unpaired two-tailed student\'s *t*-test).](nihms263881f1){#F1}

![Smad3^-/-^ mice have a reduction in TCRαβ^+^CD8αα^+^ IEL\
(**a**) Representative plots showing CD8α versus CD8β staining on TCRβ^+^ cells from wild-type (left) and *Smad3*^-/-^ (right) mice. (**b**) Frequencies of TCRβ^+^CD8αβ^+^, TCRβ^+^CD8αα^+^ and TCRβ^+^CD8^-^ IELs in wild-type (n=14) and *Smad3*^-/-^ (n=16) mice (mean ± SEM). \*p\<0.0007 (unpaired two-tailed student\'s *t*-test).](nihms263881f2){#F2}

![Over-expression of TGF-β from T cells leads to a greater population of TCRαβ^+^CD8αα^+^ IEL\
(**a**) Representative plots showing CD8α versus CD8β staining on TCRβ^+^ cells from β1^glo+^CD4-cre^+^ (8^+^ weeks old) and age-matched littermate control mice (either β1^glo-^ CD4-cre^+^, β1^glo+^ CD4-cre^-^, or β1^glo-^ CD4-cre^-^). (**b**) Frequency and (**c**) total number of CD8αβ^+^ or CD8αα^+^ TCRαβ^+^ IEL in mice from (**a**) (mean ± SEM). *n*=7 for β1^glo+^CD4- cre^+^ (black bars) and *n*=8 for littermate controls (white bars) examined in at least 3 independent experiments. \*p=0.0331, \*\*p=0.0003 (unpaired two-tailed student\'s *t*-test).](nihms263881f3){#F3}

![TGF-β-deficient mice have a reduced population of DN TCRαβ^+^CD5^+^ thymocytes\
(**a**) Representative plots showing gating of DN TCRαβ^+^CD5^+^thymocytes. (**b**) Frequency (left) and total number (center) of DN TCRαβ^+^CD5^+^thymocytes and the frequency of all DN thymocytes (right) in WT littermate control (white bars) and *Tgfb1*^-/-^ (black bars) mice. *n*=14 for *Tgfb1*^-/-^ and *n*=12 for controls; \*p\<0.003. (**c**) Representative plots showing Annexin-V versus 7-AAD staining on DN TCRαβ^+^CD5^+^thymocytes from WT (left) and *Tgfb1*^-/-^ (right) mice. (**d, e**) Histograms show Bcl-2 (**d**) and Bim (**e**) staining on DN TCRαβ^+^CD5^+^ thymocytes from WT (gray line) and *Tgfb1*^-/-^ (black line) mice. (**f-i**) Representative plots showing (**f**) Ki-67, (**g**) CD127, (**h**) α4β7 and (**i**) CD103 staining on DN TCRαβ^+^CD5^+^ thymocytes from WT and *Tgfb1*^-/-^ mice. Staining was performed on at least two mice per group and 2-5 times.](nihms263881f4){#F4}

![TGF-β induces CD8α expression on DN TCRαβ^+^CD5^+^ thymocytes\
(**a, b, c**) Quantitative PCR analysis of (**a**) CD8α, (**b**) CD8β and (**c**) Th-POK expression in FACS sorted DN TCRαβ^+^CD5^+^ thymocytes from WT thymi stimulated overnight with anti-CD3 (1μg/ml) in the absence or presence of TGF-β1 (2ng/ml). Results are presented relative to control cultures without TGF-β1 treatment. Data are representative of 2 independent experiments. \*p≤0.0244 (paired two-tailed student\'s *t*-test).](nihms263881f5){#F5}

![TGF-β is required to maintain expression of CD8 on peripheral T cells\
(**a, c**) Representative plots showing CD4 versus CD8α (top panel) and CD8α versus CD8β (bottom panel) staining on TCRβ^+^ splenocytes from (**a**) WT (left) and *Tgfb1*^-/-^ (right) mice, and (**c**) *Tgfbr1*^f/+^CD4-cre^+^ and *Tgfbr1*^f/f^CD4-cre^+^ mice. (**b, d**) Representative histograms showing CD8α, CD8β and CD4 staining on (**b**) WT control (shaded) and *Tgfb1*^-/-^ (black line) cells and (**d**) *Tgfbr1*^f/+^CD4-cre^+^ (shaded) and *Tgfbr1*^f/f^CD4-cre^+^ (black line) cells. Data represent staining on at least 2 mice per group examined in at least 3 independent experiments.](nihms263881f6){#F6}

![TGF-β induces expression of CD8α on peripheral CD4^+^ T cells in a Smad3-dependent manner\
(**a**) CD4^+^CD25^−^ cells were cultured with anti-CD3 in the absence or presence of TGF-β1 (2ng/ml) for 4 days. Representative plots showing CD4 versus CD8α staining on cultured cells, numbers reflect the frequency of CD8α^+^CD4^+^TCRβ^+^ cells or the percent of CD4^+^ cells in the starting population (purified cells). Representative histogram showing frequency of CD8β^−^ (CD8αα^+^) or CD8β^+^ (CD8αβ^+^) cells in the CD8α^+^CD4^+^TCRβ^+^ population. Data shown are representative of 5 independent experiments. (**b**) Quantitative PCR analysis of CD8α (left) and CD8β (right) expression in CD4^+^CD25^-^ cultures at 6 and 48 hours, stimulated with anti-CD3 (white bars) or anti-CD3 plus TGF-β1 (black bars). Results are presented relative to control cultures without TGF-β1 treatment. Data are representative of 4 independent experiments. \*p\<0.005 (paired two-tailed student\'s *t*-test). **c**, CD4^+^CD25^−^ cells from WT littermate control or *Smad3*^-/-^ mice were cultured with anti-CD3 indicated concentrations of TGF-β1. Representative plots showing CD4 versus CD8α staining on cultured cells from WT (top) and *Smad3*^-/-^ (bottom) cultures, Bar graph shows frequency of CD8α^+^CD4^+^TCRβ^+^ cells following the different culture conditions (mean ± SEM). Data represent 3 independent experiments. p\<0.004 (unpaired two-tailed student\'s *t*-test). (**d**) Quantitative PCR analysis of CD8α expression in WT (white bars) and *Smad3*^-/-^ (black bars) CD4^+^CD25^-^ T cell cultures stimulated with anti-CD3 or anti-CD3 plus TGF-β1 for 6 hours. Results are presented relative control cultures without TGF-β1 treatment. Data are representative of 2 independent experiments. \*p\<0.005 (paired two-tailed student\'s *t*-test).](nihms263881f7){#F7}

![Expression of Th-POK and Runx3 in CD4^+^CD8a^-^ and CD4^+^CD8a^+^ cells\
(**a-c**) CD4^+^CD25^-^ cells were cultured with anti-CD3 in the absence or presence of TGF-β1 (2ng/ml) for 4 days. (**a**) Representative histogram showing Runx3-RFP expression in Runx3-RFP^-^ CD4^+^CD8α^-^ cells from anti-CD3 stimulated cultures (grey histogram), Runx3-RFP^+^ CD4^+^CD8α^-^ cells from un-stimulated cultures (orange histogram), Runx3-RFP^+^ CD4^+^CD8α^-^ cells from anti-CD3 plus media stimulated cultures (blue line), Runx3-RFP^+^ CD4^+^CD8α^-^ from anti-CD3 plus TGF-β1 stimulated cultures (black line) and induced Runx3-RFP^+^ CD4^+^CD8α^+^ from anti-CD3 plus TGF-β1 stimulated cultures (green line). (**b**) Representative histogram showing Th-POK-GFP expression in GFP^-^ CD4^+^CD8α^-^ cells from anti-CD3 stimulated cultures (shaded histogram), GFP^+^ CD4^+^CD8α^-^ cells from unstimulated cultures (red line), from anti-CD3 plus media stimulated cultures (blue line) or from anti-CD3 plus TGF-β1 stimulated cultures (black line). (**c**) Representative plot showing CD4^+^CD8α^-^ and CD4^+^CD8α^+^ populations generated in anti-CD3 plus TGF-β cultures. Representative histogram showing Th-POK-GFP expression in CD4^+^CD8α^-^ (shaded) and CD4^+^CD8α^+^ (black line) cells. Data shown (a-c) are representative of 3 independent experiments. (**d, e**) CD4^+^CD25^-^ cells from (**d**) *Zbtb7b*^+/+^ (WT) and *Zbtb7b*^+/-^ (heterozygous) mice and (**e**) Th-POK transgenic and littermate control mice were cultured with anti-CD3 (left) or anti-CD3 plus anti-28 (right) in the absence or presence of 1ng/ml TGF-β1 for 4 days. Bar graph shows frequency of CD8α^+^CD4^+^TCRβ^+^ cells at day 4 (mean ± SEM). Data represent 3 independent experiments (*Zbtb7b*^+/-^ mice) and 2 independent experiments (Th-POK-transgenic mice). p\<0.0202 (unpaired two-tailed student\'s *t*-test).](nihms263881f8){#F8}
